Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 6/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700570 | 1.00 | ARG1 (0.37) | ARG1ARG2GRIK1GRIK2DDAH1 | |
| SCHEMBL16447139 | 0.86 | ARG1 (0.42) | ARG1ARG2GRIK1GRIK2DDAH1 | |
| SCHEMBL17852295 | 0.86 | ARG1 (0.42) | ARG1ARG2GRIK1GRIK2DDAH1 | |
| SCHEMBL20178599 | 0.86 | ARG1 (0.42) | ARG1ARG2GRIK1GRIK2DDAH1 | |
| SCHEMBL19514769 | 0.81 | MEN1 (0.39) | CASP1MAPTCACNA1BAPBA1SMN1; SMN2 | |
| SCHEMBL17324271 | 0.80 | GFPT1 (0.45) | GRIK1GRIK2DDAH1CASP1MAPT | |
| SCHEMBL25660591 | 0.80 | GFPT1 (0.45) | GRIK1GRIK2DDAH1CASP1MAPT | |
| Hydrochloric Acid SCHEMBL31496724 | 0.78 | GFPT1 (0.44) | GRIK1GRIK2DDAH1CASP1MAPT | |
| SCHEMBL17852438 | 0.77 | ARG1 (0.42) | ARG1ARG2GRIK1GRIK2DDAH1 | |
| SCHEMBL16448162 | 0.77 | ARG1 (0.42) | ARG1ARG2GRIK1GRIK2DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566334-B1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2566335-B1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-103025165-B | From the controlled release of macromolecular conjugates | 普罗林科斯有限责任公司 | 2016-06-08 | — | — | CN | disclosed |
| US-8946405-B2 | Controlled release from solid supports | PROLYNX LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8754190-B2 | Controlled release from macromolecular conjugates | PROLYNX LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8703907-B2 | Controlled drug release from dendrimers | PROLYNX LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC | 2013-05-09 | — | — | US | disclosed |
| CN-103025164-A | Controlled drug release from solid supports | PROLYNX LLC | 2013-04-03 | — | — | CN | disclosed |
| CN-103025165-A | Controlled release from macromolecular conjugates | PROLYNX LLC | 2013-04-03 | — | — | CN | disclosed |
| EP-2571496-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | Prolynx Llc (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2566334-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2566335-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140376-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140392-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140393-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | SLC43A1, ABCB1, NAPA | ARG1 778/4885ARG2 1014/4885GRIK1 4629/4885 |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | SLC43A1, SLC47A1, SLC47A2 | ARG1 1360/4885ARG2 756/4885GRIK1 724/4885 |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | ABCB1, ABCB11, GUSB | ARG1 3168/4885ARG2 3330/4885GRIK1 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.